-
Founded in:
2000-04-27 -
Country:
China -
Address:
No. 567, Liufeng Road, Hedong Industrial Park, Wuzhong Economic Development Zone, Suzhou -
Tax NO.:
91320500720535900Q -
Registered Funds:
38.526778 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Hydroxychloroquine sulfate |
No specific description provided
More
No specific description provided |
747-36-4 | 39 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Leflunomide |
Extract from the above information
More
Extract from the above information |
75706-12-6 | 17 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Leflunomide |
This product is an isoxazole immunosuppressant with antiproliferative activity. Its mechanism of action is mainly to inhibit the activity of dihydroorotate dehydrogenase, thereby affecting the pyrimidine synthesis of activated lymphocytes. In vitro and in vivo tests have shown that this product has anti-inflammatory effects. The in vivo activity of leflunomide is mainly produced through its active metabolite A771726 (M1).
More
This product is an isoxazole immunosuppressant with antiproliferative activity. Its mechanism of action is mainly to inhibit the activity of dihydroorotate dehydrogenase, thereby affecting the pyrimidine synthesis of activated lymphocytes. In vitro and in vivo tests have shown that this product has anti-inflammatory effects. The in vivo activity of leflunomide is mainly produced through its active metabolite A771726 (M1). |
75706-12-6 | 17 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Leflunomide |
This product is an isoxazole immunosuppressant with antiproliferative activity. Its mechanism of action is mainly to inhibit the activity of dihydroorotate dehydrogenase, thereby affecting the pyrimidine synthesis of activated lymphocytes. In vitro and in vivo tests have shown that this product has anti-inflammatory effects. The in vivo activity of leflunomide is mainly produced through its active metabolite A771726 (M1).
More
This product is an isoxazole immunosuppressant with antiproliferative activity. Its mechanism of action is mainly to inhibit the activity of dihydroorotate dehydrogenase, thereby affecting the pyrimidine synthesis of activated lymphocytes. In vitro and in vivo tests have shown that this product has anti-inflammatory effects. The in vivo activity of leflunomide is mainly produced through its active metabolite A771726 (M1). |
75706-12-6 | 17 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Leflunomide |
This product is an isoxazole immunosuppressant with antiproliferative activity. Its mechanism of action is mainly to inhibit the activity of dihydroorotate dehydrogenase, thereby affecting the pyrimidine synthesis of activated lymphocytes. In vitro and in vivo tests have shown that this product has anti-inflammatory effects. The in vivo activity of leflunomide is mainly produced through its active metabolite A771726 (M1).
More
This product is an isoxazole immunosuppressant with antiproliferative activity. Its mechanism of action is mainly to inhibit the activity of dihydroorotate dehydrogenase, thereby affecting the pyrimidine synthesis of activated lymphocytes. In vitro and in vivo tests have shown that this product has anti-inflammatory effects. The in vivo activity of leflunomide is mainly produced through its active metabolite A771726 (M1). |
75706-12-6 | 17 |